AngioDynamics (NASDAQ:ANGO) Posts Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) issued its earnings results on Tuesday. The medical instruments supplier reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.09, RTT News reports. The company had revenue of $80.16 million for the quarter, compared to analyst estimates of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.17%. The business’s revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.06) EPS. AngioDynamics updated its FY 2026 guidance to -0.350–0.250 EPS.

AngioDynamics Stock Down 0.6%

AngioDynamics stock opened at $8.60 on Thursday. AngioDynamics has a 52 week low of $5.83 and a 52 week high of $13.50. The firm’s 50-day simple moving average is $9.88 and its 200 day simple moving average is $10.07. The firm has a market capitalization of $349.25 million, a PE ratio of -10.36 and a beta of 0.60.

Analyst Ratings Changes

Several equities research analysts have commented on ANGO shares. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of AngioDynamics in a research report on Wednesday. Canaccord Genuity Group set a $17.00 target price on shares of AngioDynamics and gave the stock a “buy” rating in a research report on Wednesday. Finally, Lake Street Capital started coverage on shares of AngioDynamics in a research report on Wednesday. They set a “buy” rating and a $24.00 target price on the stock.

Institutional Investors Weigh In On AngioDynamics

An institutional investor recently raised its position in AngioDynamics stock. Goldman Sachs Group Inc. boosted its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 9.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 259,226 shares of the medical instruments supplier’s stock after purchasing an additional 22,658 shares during the quarter. Goldman Sachs Group Inc. owned about 0.64% of AngioDynamics worth $2,434,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.